Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has issued an announcement.
Beijing Biostar Pharmaceuticals Co., Ltd. announced its audited consolidated results for the year ending December 31, 2024, showing a 7.9% increase in revenue and a 24.2% reduction in loss before taxation compared to the previous year. The company has made significant progress in advancing its R&D pipeline, particularly with its core product, Utidelone Injection, which is undergoing multiple clinical trials for various cancer treatments. The development of Utidelone Capsule is also progressing, with promising clinical data supporting its potential as a convenient and effective cancer treatment option.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology-driven biopharmaceutical company based in China, focused on developing innovative drugs in oncology. The company has developed three core technology platforms for the R&D of microbial metabolite new drugs, with one commercialized product and 19 R&D pipeline projects. Their core product, Utidelone Injection, is a chemotherapy drug approved for relapsed or metastatic breast cancer.
Average Trading Volume: 371,000
Technical Sentiment Signal: Strong Sell
For a thorough assessment of 2563 stock, go to TipRanks’ Stock Analysis page.